Compositions and Methods for Altering Pancreas or Liver Function

• US 20100086525A1
• Filed: 04/18/2008
• Published: 04/08/2010
• Est. Priority Date: 05/03/2007
• Status: Abandoned Application

• Current Assignee: Fox Chase Cancer Center
• Original Assignee: Fox Chase Cancer Center
• Inventors: Zaret, Kenneth S., Kashima, Yasushige
• Application Number:
  US12/598,439
• Publication Number:
  US 20100086525A1
• Time in Patent Office: Days
• US Class Current: 424/93.700
• CPC Class Codes: A61K 38/19 Cytokines; Lymphokines; Interferons
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 1/18 for pancreatic disorders, e.g. pancreatic enzymes
• CPC Class Codes: C12N 2501/585 Integrins
• CPC Class Codes: C12N 5/0676 Pancreatic cells

Abstract

Methods for altering pancreatic and liver cell function are provided, wherein the compositions and methods are based on use of osteopontin or on altering the activity of osteopontin.

Claims

1. A method for inducing differentiation of an endodermal cell or a progenitor cell into a pancreatic or liver cell comprising contacting an endodermal cell or a progenitor cell with an effective amount of osteopontin thereby inducing differentiation of the endodermal cell or the progenitor cell into a pancreatic or liver cell.

2. The method of claim 1 wherein said cell is a partially differentiated liver or pancreatic progenitor cell.

8. A composition comprising an isolated pancreatic or liver cell differentiated by the method of claim 1.

9. A pharmaceutical composition comprising isolated pancreatic or liver cells differentiated by the method of claim 1 and a pharmaceutically acceptable vehicle.

3. A method for altering liver cell function comprising contacting a liver cell with an effective amount of osteopontin, wherein contact of the cell with osteopontin results in an alteration in the function of the liver cell.

4. A method for altering liver cell function comprising contacting a liver cell with an effective amount of a composition comprising an osteopontin protein, an osteopontin antibody, an osteopontin mimetic, an osteopontin agonist, an osteopontin antagonist, a mutated osteopontin protein, or an osteopontin variant or fragment thereof, formulated in a pharmaceutically acceptable vehicle, wherein contact of the cell with said composition results in an alteration in the function of the liver cell.

5. A method for preventing or treating a disease of the liver in a patient comprising administering to a patient a therapeutically effective amount of a composition comprising osteopontin formulated in a pharmaceutically acceptable vehicle, wherein administration of said composition results in prevention or treatment of a disease of the liver.

6. A method for preventing or treating a disease of the liver in a patient comprising administering to a patient a therapeutically effective amount of a composition comprising an osteopontin protein, an osteopontin antibody, an osteopontin mimetic, an osteopontin agonist, an osteopontin antagonist, a mutated osteopontin protein, or an osteopontin variant or fragment thereof, formulated in a pharmaceutically acceptable vehicle, wherein administration of the composition results in prevention or treatment of a disease of the liver.

7. A method of restoring function of a damaged liver tissue which comprises contacting a damaged liver tissue with an effective amount of osteopontin, wherein contact of the damaged tissue with osteopontin results in a restoration of function of the damaged tissue.